Glioblastoma typically progresses from diagnosis to death in about 15 to 18 months with standard treatment, making it the most aggressive primary brain cancer in adults. The disease follows a broadly recognizable arc: initial symptoms, surgery and chemoradiation, a period of relative stability, eventual recurrence, accelerating functional decline, and an end-of-life phase with distinct neurological symptoms. But the pace and character of that arc vary enormously depending on the tumor’s molecular profile, its location in the brain, and how the individual responds to treatment.
How Glioblastoma Grows Inside the Brain
Understanding what to expect starts with understanding how this tumor behaves, because glioblastoma does not grow the way most cancers do. Rather than forming a neat, contained mass, it sends microscopic tendrils of cells outward into surrounding brain tissue. These invading cells preferentially travel along white matter tracts, the bundles of nerve fibers that connect different brain regions. Research measuring the direction of tumor growth has confirmed that expansion parallel to these fiber bundles is significantly more common than growth perpendicular to them.1PubMed Central. The Direction of Tumour Growth in Glioblastoma Patients When tumor cells enter white matter, they even begin mimicking the gene activity of the brain’s own white-matter cells, switching on programs associated with the oligodendrocyte lineage as if adapting to their new environment.2PubMed Central. The white matter is a pro-differentiative niche for glioblastoma
This diffuse invasion pattern is the main reason surgery alone cannot cure glioblastoma. Even when a neurosurgeon achieves what looks like a complete removal on imaging, invisible clusters of tumor cells have already migrated beyond the resection cavity. The cells that will eventually cause recurrence are often centimeters away from the original tumor border. Researchers now also understand that glioblastoma cells form functional synaptic connections with healthy neurons, essentially wiring themselves into the brain’s circuitry. These connections allow tumor cells to receive electrical signals from neurons, which appear to fuel further growth and invasion.3PubMed Central. Neuron-Glioma Synapses in Tumor Progression The tumor, in other words, is not just sitting inside the brain. It is participating in brain activity.
Early Symptoms and Getting a Diagnosis
The first symptoms of glioblastoma depend almost entirely on where in the brain the tumor arises. Seizures are one of the most common initial presentations and can be the very first sign in early-stage tumors.4Elsevier / Neurochirurgie. Early presentation of primary glioblastoma Other early symptoms include persistent headaches that worsen over days to weeks, weakness on one side of the body, vision changes, speech difficulties, or personality and behavioral shifts. Because many of these symptoms overlap with common conditions like migraines or stress, there is sometimes a frustrating delay between the first symptom and the scan that reveals the tumor.
MRI is the primary diagnostic tool. Glioblastomas have a characteristic appearance: an irregularly enhancing mass often with a central area of dead tissue surrounded by a rim of active tumor, plus significant surrounding swelling. Advanced MRI techniques help clinicians later in the disease course, too, particularly when they need to determine whether a suspicious area on follow-up imaging represents tumor regrowth or radiation damage. Perfusion-weighted imaging can distinguish the two because recurring tumor tends to have significantly higher blood volume than radiation-injured tissue.5PubMed Central. Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging One study found this approach achieved diagnostic accuracy around 86%.6PubMed. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma
Molecular Markers That Shape the Timeline
Not all glioblastomas are biologically identical, and two molecular markers in particular strongly influence how the disease unfolds. The first is MGMT promoter methylation status. MGMT is a repair enzyme that can undo the damage caused by the standard chemotherapy drug temozolomide. When the gene encoding MGMT is silenced through a chemical modification called methylation, the tumor is less able to repair itself after chemotherapy and tends to respond better to treatment. MGMT methylation status is widely accepted as a prognostic marker, though its precise role in guiding treatment decisions remains debated.7PubMed Central. MGMT Status as a Clinical Biomarker in Glioblastoma
The second key marker is IDH mutation status. A prospective registry study found that the combination of these markers dramatically stratifies survival. Patients whose tumors carried both an IDH mutation and MGMT methylation had a median survival of about 36 months. Those with neither favorable marker had a median survival of just 15 months. Each marker independently predicted improved survival even after accounting for age and functional status.8PubMed Central. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry When someone asks “how long do I have,” the honest answer depends heavily on these molecular details.
Standard First-Line Treatment
The backbone of glioblastoma treatment has not fundamentally changed since 2005, when a landmark trial established what is often called the Stupp protocol. After maximal safe surgical removal of the tumor, patients receive about six weeks of daily radiation therapy combined with a daily oral dose of temozolomide, followed by six additional monthly cycles of temozolomide alone.9PubMed. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma That trial showed a meaningful survival advantage over radiation alone, and the regimen has been the global standard ever since.
A more recent addition to this framework is tumor-treating fields, a wearable device that delivers low-intensity alternating electric fields to the scalp. The device disrupts cell division and has several other anti-tumor effects. When added to standard temozolomide maintenance therapy after chemoradiation, tumor-treating fields extended median overall survival by about five months compared to temozolomide alone, pushing the median above 20 months, without significantly increasing systemic side effects.10British Journal of Cancer. Tumour treating fields therapy for glioblastoma: current advances and future directions The FDA approved the device for newly diagnosed glioblastoma in 2015.11PubMed Central. Tumor-Treating Fields in Glioblastomas: Past, Present, and Future The practical challenge is compliance: the device must be worn for at least 18 hours a day, and patients must shave their heads for electrode contact. For some people the lifestyle burden feels manageable; for others it does not.
Why the Blood-Brain Barrier Matters More Than People Think
A common assumption, even among clinicians, is that the blood-brain barrier is essentially destroyed throughout a glioblastoma. After all, the tumor “lights up” on contrast MRI, which means the barrier is breached in those areas. But this picture is misleading. While the barrier is indeed disrupted within the enhancing tumor core, a clinically significant fraction of tumor cells exist in regions where the barrier remains intact.12PubMed Central. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data Those cells, shielded by a functional barrier, may never be exposed to adequate drug concentrations. This is a major reason why systemically delivered drugs often fail against glioblastoma: the very cells most responsible for recurrence may be the ones drugs cannot reach. Research using whole-brain vascular imaging has confirmed that barrier permeability increases gradually during tumor progression, with drug-carrying particles initially restricted to the smallest vessels.13PubMed Central. Construction of a whole-brain panorama for glioma vasculature reveals tumor heterogeneity and blood-brain barrier disruption
Recurrence and Drug Resistance
Virtually all glioblastomas recur, typically within about seven to ten months of initial treatment. The recurrence usually happens near the original tumor site but can occasionally appear in a distant part of the brain. At recurrence, the tumor is often more resistant to the treatments that were used first.
Temozolomide resistance is driven by multiple overlapping mechanisms. The best-known is overexpression of the MGMT repair enzyme, which directly reverses the DNA damage caused by the drug.14PubMed Central. Temozolomide resistance in glioblastoma multiforme But that is far from the whole story. Other DNA repair systems can compensate when the primary pathway is blocked, and glioblastoma stem cells, a small population of cells with self-renewal ability, appear especially resistant to chemotherapy and capable of regenerating the tumor. Additional resistance mechanisms include autophagy (a cellular self-recycling process that helps tumor cells survive under stress), changes in gene regulation, and signaling through aberrant molecular pathways.15PubMed Central. Mechanisms of temozolomide resistance in glioblastoma – a comprehensive review16Neurologia medico-chirurgica. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
Treatment options at recurrence are limited and less effective than frontline therapy. Some patients undergo a second surgery or re-irradiation. Bevacizumab, a drug that starves tumors by blocking blood vessel growth, is FDA-approved for recurrent glioblastoma and can shrink tumors on imaging and reduce brain swelling. Before bevacizumab, six-month progression-free survival in recurrent glioblastoma trials ranged from roughly 9 to 15%.17PubMed Central. Use of bevacizumab in recurrent glioblastoma Whether bevacizumab truly extends overall survival or primarily improves symptoms and delays visible progression on scans has been a persistent question, and randomized data have not convincingly resolved it.18The Lancet Oncology. First-line treatment with lomustine plus bevacizumab versus lomustine alone in recurrent glioblastoma (BELOB) Other approaches under study include immunotherapy, oncolytic viruses, and targeted agents, but no breakthrough for recurrent disease has been established.19PubMed Central. Recurrent Glioblastoma: A Review of the Treatment Options
Cognitive and Functional Decline
Cognitive decline is one of the most feared aspects of glioblastoma and one of the hardest to talk about. While the tumor is controlled, cognitive function tends to remain relatively stable. In one study, the proportion of patients without tumor progression who experienced significant cognitive decline stayed consistent at about 13 to 18% across two years of follow-up. But when the tumor begins to progress again, cognitive scores drop sharply. Declining scores on simple cognitive tests often preceded radiographic evidence of progression on MRI, making cognitive changes an early warning sign that the tumor is growing before imaging catches it.20PubMed. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma
The specific deficits depend on tumor location. Tumors in the left hemisphere may impair language, while right-hemisphere tumors are more likely to affect spatial awareness and emotional processing. Frontal lobe involvement often produces personality changes, apathy, and impaired judgment. These changes are frequently more distressing to family members than to the patient, since the patient may not fully recognize the shift in their own cognition or behavior.
Managing Symptoms Along the Way
Brain swelling around the tumor, called peritumoral edema, is a major contributor to neurological symptoms throughout the disease. The standard treatment is dexamethasone, a potent steroid. After surgery, doses up to 16 mg daily are recommended for symptomatic patients, with a tapering schedule as soon as symptoms allow. Patients with limited life expectancy can be maintained on a low daily dose.21PubMed Central. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline
The problem is that dexamethasone itself causes substantial side effects: muscle weakness, weight gain, elevated blood sugar, mood disturbances, bone thinning, and increased infection risk, all of which worsen with higher doses and longer use. There is also growing evidence that dexamethasone may have adverse effects on tumor biology itself, potentially promoting tumor progression at the molecular level even while it controls swelling.22PubMed Central. Controversial roles for dexamethasone in glioblastoma – Opportunities for novel vascular targeting therapies This tension between symptom relief and potential harm is something patients and their care teams navigate constantly. Seizure medications are the other mainstay of symptom management, and they require careful selection since some anti-seizure drugs interact with chemotherapy.
What the End-of-Life Phase Looks Like
The final weeks of glioblastoma look different from end-stage disease in most other cancers. The predominant symptoms are neurological. A large study of end-of-life symptoms found that the majority of patients experienced loss of consciousness and difficulty swallowing, often arising in the last week. Seizures occurred in nearly half of patients during the end-of-life phase and in about a third during the final week. Progressive neurological deficits, incontinence, cognitive decline, and headache were also common.23PubMed Central. Symptoms and problems in the end-of-life phase of high-grade glioma patients
A prospective study assessing symptoms in the final two weeks found that the most severe symptoms were drowsiness, difficulty concentrating, fatigue, difficulty speaking, weakness, and difficulty understanding. All of these worsened significantly as death approached. Hospice was contacted at a median of just three weeks before death, a timeline many palliative care specialists consider too late for optimal support.24Neuro-Oncology Practice. Prospective assessment of end-of-life symptoms and quality of life in patients with high-grade glioma
Clinical tumor progression was the direct cause of death in about 77% of patients in one retrospective study, with infection, intratumoral bleeding, seizures, and pulmonary embolism accounting for most of the remainder. About half of patients died at home with hospice care, and roughly a quarter died in an inpatient hospice facility.25PubMed Central. Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study Advance care planning conversations are recommended after the completion of initial chemoradiation, when patients are typically still cognitively intact and able to articulate their wishes.26PubMed Central. Palliative care in glioblastoma patients: a systematic review Family members often prefer these conversations to happen earlier, at diagnosis, though patients themselves are more divided on timing.
The Burden on Caregivers
Glioblastoma exerts a particular toll on the people providing care, and that toll correlates more closely with the patient’s cognitive and behavioral symptoms than with their physical decline. In a study examining caregiver well-being, patient confusion and personality or mood changes were the strongest independent predictors of worse emotional health in caregivers. Confusion also predicted poor caregiver social health, general health, inability to work, and diminished overall quality of life.27PubMed Central. Caregiver burden by treatment and clinical characteristics of patients with glioblastoma Caregiving for more than 12 hours per week and managing medication administration were additional independent contributors.
A qualitative study of spouse caregivers identified four phases of the disease trajectory: an acute phase in the first two to four months after diagnosis, a prolonged period of living with disease progression, the end-of-life stage, and bereavement. Caregivers reported feeling unprepared and unsupported across all phases, with the greatest emotional impact during the acute phase and the “living with progression” period. A recurring theme was the desire for more education about what to expect.28Cancer Research. Spouse caregivers of patients with glioblastoma report unmet needs throughout the disease trajectory This is one of the practical reasons articles like this one exist: knowing the trajectory, even in broad strokes, can ease some of the shock that compounds grief.
Immunotherapy and Other Emerging Approaches
The glioblastoma research field has spent the last decade chasing a therapy that could meaningfully shift survival beyond what the Stupp protocol achieves. Immunotherapy, which has transformed outcomes in cancers like melanoma and lung cancer, has been largely disappointing in glioblastoma so far. The brain’s immune environment is suppressive, dominated by immune cells that dampen rather than amplify anti-tumor responses. Conventional immunotherapy approaches, including checkpoint inhibitors, CAR-T cells, and cancer vaccines, have produced low response rates when used individually.29Advanced Therapeutics. Combinatory Immunotherapy for Glioblastoma Treatment
CAR-T cell therapy is generating cautious optimism. Recent trials have shown that these engineered immune cells can be delivered intravenously rather than requiring direct injection into the brain, and that products targeting multiple tumor antigens can produce measurable shrinkage of intracranial tumors. But persistent function is limited by the tumor’s ability to shed targeted markers and by the immunosuppressive local environment that exhausts the T cells.30Journal for ImmunoTherapy of Cancer. Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions Combination strategies, pairing immunotherapy with radiation, chemotherapy, or other immune-modulating treatments, are increasingly seen as the most promising path forward, though robust clinical evidence is still being gathered.
Liquid biopsies represent another area of active development, not as a treatment but as a way to track the tumor without repeated brain scans. Blood-based tests that detect tumor-derived DNA or other markers could eventually allow clinicians to monitor disease progression and treatment response through a simple blood draw.31PubMed Central. Liquid biopsies for the monitoring of gliomas and brain metastases in adults
The Ketogenic Diet Question
Patients and families frequently ask about the ketogenic diet as a complementary approach to glioblastoma treatment. The biological rationale is real: glioblastoma cells rely heavily on glucose for energy, and a ketogenic diet sharply reduces blood glucose while raising ketone levels, which normal brain cells can use but tumor cells metabolize poorly.32PubMed Central. The role of metabolic therapy in treating glioblastoma multiforme A small study of 16 glioma patients on ketogenic metabolic therapy reported encouraging results, with a mean progression-free survival of about 20 months during the therapy period.33PubMed Central. Ketogenic Metabolic Therapy for Glioma A systematic review concluded that the diet appears to be associated with improved survival in brain tumor patients, but emphasized that larger human trials are needed before the diet’s anti-tumor effects can be considered established.34PubMed Central. Systematic Review and Clinical Insights: The Role of the Ketogenic Diet in Managing Glioblastoma in Cancer Neuroscience
The honest summary is that the ketogenic diet is biologically plausible and safe enough that many neuro-oncologists are comfortable with patients trying it alongside standard treatment, but it is not proven to extend survival. The existing studies are small and lack the randomized, controlled designs needed to draw firm conclusions. For patients who find dietary action empowering amid an otherwise difficult situation, there is little harm in trying it under medical supervision. But it should not replace standard therapy.